JP2019536816A - 高血圧の処置のための組成物 - Google Patents

高血圧の処置のための組成物 Download PDF

Info

Publication number
JP2019536816A
JP2019536816A JP2019547198A JP2019547198A JP2019536816A JP 2019536816 A JP2019536816 A JP 2019536816A JP 2019547198 A JP2019547198 A JP 2019547198A JP 2019547198 A JP2019547198 A JP 2019547198A JP 2019536816 A JP2019536816 A JP 2019536816A
Authority
JP
Japan
Prior art keywords
dose
pharmaceutical composition
diuretic
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019547198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536816A5 (cg-RX-API-DMAC7.html
Inventor
ロジャース，アンソニー
チャウ，クララ
Original Assignee
ザ ジョージ インスティテュート フォー グローバル ヘルス
ザ ジョージ インスティテュート フォー グローバル ヘルス
ザ ユニバーシティー オブ シドニー
ザ ユニバーシティー オブ シドニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジョージ インスティテュート フォー グローバル ヘルス, ザ ジョージ インスティテュート フォー グローバル ヘルス, ザ ユニバーシティー オブ シドニー, ザ ユニバーシティー オブ シドニー filed Critical ザ ジョージ インスティテュート フォー グローバル ヘルス
Publication of JP2019536816A publication Critical patent/JP2019536816A/ja
Publication of JP2019536816A5 publication Critical patent/JP2019536816A5/ja
Priority to JP2023017160A priority Critical patent/JP2023095844A/ja
Priority to JP2025036716A priority patent/JP2025102796A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019547198A 2016-11-15 2017-11-14 高血圧の処置のための組成物 Pending JP2019536816A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023017160A JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物
JP2025036716A JP2025102796A (ja) 2016-11-15 2025-03-07 高血圧の処置のための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/352,425 US10369156B2 (en) 2016-11-15 2016-11-15 Compositions for the treatment of hypertension
US15/352,425 2016-11-15
PCT/IB2017/001524 WO2018091967A1 (en) 2016-11-15 2017-11-14 Compositions for the treatment of hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017160A Division JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物

Publications (2)

Publication Number Publication Date
JP2019536816A true JP2019536816A (ja) 2019-12-19
JP2019536816A5 JP2019536816A5 (cg-RX-API-DMAC7.html) 2020-12-24

Family

ID=62107049

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547198A Pending JP2019536816A (ja) 2016-11-15 2017-11-14 高血圧の処置のための組成物
JP2023017160A Pending JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物
JP2025036716A Pending JP2025102796A (ja) 2016-11-15 2025-03-07 高血圧の処置のための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023017160A Pending JP2023095844A (ja) 2016-11-15 2023-02-07 高血圧の処置のための組成物
JP2025036716A Pending JP2025102796A (ja) 2016-11-15 2025-03-07 高血圧の処置のための組成物

Country Status (8)

Country Link
US (2) US10369156B2 (cg-RX-API-DMAC7.html)
EP (2) EP3541379A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019536816A (cg-RX-API-DMAC7.html)
CN (2) CN110366414A (cg-RX-API-DMAC7.html)
AU (3) AU2017359607A1 (cg-RX-API-DMAC7.html)
CA (1) CA3043835A1 (cg-RX-API-DMAC7.html)
TW (1) TWI799397B (cg-RX-API-DMAC7.html)
WO (1) WO2018091967A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
KR20250052479A (ko) 2017-01-25 2025-04-18 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
CN117542473A (zh) * 2018-06-14 2024-02-09 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
EP3807892A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
BR112021001374A2 (pt) * 2018-07-26 2021-07-06 The George Inst For Global Health composições para o tratamento da hipertensão
WO2020041864A1 (en) * 2018-08-25 2020-03-05 Crd Pharmaceuticals Inc. Synchronize hypertensive therapy with circadian rhythm
EP4649946A1 (en) * 2024-05-16 2025-11-19 Alba Research S.r.l. Compositions for treating arterial hypertension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076632A1 (en) 2000-04-10 2001-10-18 Wald Nicholas J Formulation for the prevention of cardiovascular disease
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20050209288A1 (en) 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
WO2005099700A1 (en) * 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
EP2029137A2 (en) 2006-06-15 2009-03-04 Gilead Colorado, Inc. Antihypertensive therapy method
WO2009026517A2 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CN101450211A (zh) 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
EP2575808A1 (en) 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
CN101966190A (zh) 2010-07-17 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
CN102225203A (zh) 2011-06-29 2011-10-26 北京阜康仁生物制药科技有限公司 一种用于降低血压的药用组合物
US10918612B2 (en) 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
CN106310278A (zh) 2016-08-01 2017-01-11 深圳奥萨制药有限公司 一种含叶酸的多联降压药物组合物
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
KR20250052479A (ko) 2017-01-25 2025-04-18 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
JP2009256209A (ja) * 2006-02-17 2009-11-05 Gilead Colorado Inc 降圧療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MID-LIFE HEALTH, vol. Vol.5, No.2, pp.78-83, JPN6021049022, 2014, ISSN: 0004892819 *
KIDNEY INTERNATIONAL, vol. Vol.75, pp.752-754, JPN6021049021, 2009, ISSN: 0004892820 *

Also Published As

Publication number Publication date
EP3541379A4 (en) 2020-05-27
BR112019009859A2 (pt) 2019-08-20
CA3043835A1 (en) 2018-05-24
TWI799397B (zh) 2023-04-21
EP4574136A2 (en) 2025-06-25
JP2025102796A (ja) 2025-07-08
CN110366414A (zh) 2019-10-22
AU2023258387A1 (en) 2023-11-23
TW201828988A (zh) 2018-08-16
US20180133227A1 (en) 2018-05-17
AU2025210908A1 (en) 2025-08-21
CN116603066A (zh) 2023-08-18
JP2023095844A (ja) 2023-07-06
EP3541379A1 (en) 2019-09-25
AU2017359607A1 (en) 2019-06-06
WO2018091967A1 (en) 2018-05-24
US10369156B2 (en) 2019-08-06
US20190314383A1 (en) 2019-10-17
EP4574136A3 (en) 2025-09-17
AU2023258387B2 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
JP2019536816A (ja) 高血圧の処置のための組成物
US12465599B2 (en) Compositions for the treatment of hypertension
RU2828226C2 (ru) Композиции для лечения гипертензии
BR122024023236A2 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma
BR112019009859B1 (pt) Composição farmacêutica para o tratamento de hipertensão e uso da mesma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011